This compound played its therapy on osteoporosis primarily through inhibiting the secretion of inflammatory cytokines (IL-6, IL-1β and TNF-α) and targeting the inflammation signaling pathways such as activating MAPKs cascades and regulate the NF-κB signaling pathway (44), which are downstream signaling transduction of inflammation. Here, NFKB1 is linked to osteoporosis.